Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Deep Tank Epoetin Alfa in CKD Dialysis
NCT00156949Phase 3Completed
- Sponsor
- Amgen
- Start
- Apr 2005
- Primary completion
- Feb 2007
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
Phase 3, open-label, single-arm trial of epoetin alfa in anemia, sponsored by Amgen. Primary endpoint: Subject incidence of adverse events. Started Apr 2005; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00156949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00156949.